We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19 (SHARP COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04342156
Recruitment Status : Withdrawn (The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.)
First Posted : April 10, 2020
Last Update Posted : October 8, 2020
National Center for Infectious Diseases
Singapore Clinical Research Institute
Singapore Eye Research Institute
Saw Swee Hock School of Public Health
Duke-NUS Graduate Medical School
Netherlands: Ministry of Health, Welfare and Sports
Information provided by (Responsible Party):
Tan Tock Seng Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : October 2020